These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
    Author: Dutta S, Zhang Y, Lee LL, O'Dea R.
    Journal: Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556.
    Abstract:
    Divalproex sodium extended-release tablet (divalproex-ER), 500 mg strength, is approved for use in the prophylaxis of migraine headaches and epilepsy. The bioavailability of novel 250 mg divalproex-ER formulations, under development to allow greater flexibility in dosing, was compared with the available 500 mg divalproex-ER in a single-dose, fasting and nonfasting, randomized, open-label, crossover study in healthy adult volunteers. One group of 15 subjects was dosed after a 10 h overnight fast and another group of 24 subjects was dosed after a high-fat breakfast. Plasma valproic acid concentration-time profiles were used to assess pharmacokinetics. Bioequivalence assessments were made via the 90% confidence interval for maximum plasma valproic acid concentration (C(max)) and the area under the concentration-time curve from time zero to infinity (AUC(infinity)). The relative bioavailability point estimates (90% confidence interval) for C(max) and AUC(infinity) were 1.05 (0.94-1.16) and 0.95 (0.83-1.09) under fasting conditions, and 1.01 (0.91-1.12) and 0.97 (0.87-1.08) under nonfasting conditions, respectively. The test 250 mg tablet formulation was bioequivalent to the reference 500 mg tablet formulation, under both fasting and nonfasting conditions, as the 90% confidence intervals for both C(max) and AUC(infinity) were within the 0.80-1.25 interval.
    [Abstract] [Full Text] [Related] [New Search]